Calian Group Ltd. has won a contract to support a Phase 2 Clinical Trial of ZYUS Life Science?s Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. Calian's full-service Contract Research Organization (CRO) will apply its extensive clinical trial management experience to support a Phase 2 Clinical Trial for Trichomylin softgel capsules. The trial will be structured as a double-blinded, placebo-controlled, randomized, multiple dose escalation study.

Trichomylin softgel capsules have been formulated with a proprietary fixed-dose combination, specifically designed for the management of chronic pain. The trial will assess the preliminary efficacy, safety and tolerability of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. Calian will provide full-service, end-to-end expertise to support this trial, including medical writing, regulatory affairs, clinical operations, site monitoring, data management, medical monitoring and quality assurance.